Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Eisai Co., Ltd. (OTC: ESALF).

Full DD Report for ESALF

You must become a subscriber to view this report.

Recent News from (OTC: ESALF)

Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting
Latest Data on Lenvima (Lenvatinib) / Keytuda (Pembrolizumab) Combination Therapy to be Presented TOKYO, May 17, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered multiple receptor tyros...
Source: ACN Newswire
Date: May, 16 2018 22:58
Eisai's (ESALF) CEO Haruo Naito on Q4 2017 Results - Earnings Call Transcript
Eisai Co. (ESALF) Q4 2017 Results Conference Call May 15, 2018 03:00 AM ET Executives Haruo Naito - Representative Corporate Officer and CEO Ryohei Yanagi - CFO Takashi Owa - Chief Medicine Creation Officer-Oncology Analysts Kazuaki Hashiguchi - Daiwa Securities Atsushi S...
Source: SeekingAlpha
Date: May, 15 2018 22:27
Eisai: Rights to Non-Opiod Severe Chronic Pain Treatment Prialt Transferred to Riemser
TOKYO, Apr 23, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive development and marketing rights for the non-opioid severe chronic pain treatment Prialt (ziconotide acetate) in Europe to Riemser Pharma GmbH. Under the agre...
Source: ACN Newswire
Date: April, 22 2018 20:43
Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
TOKYO, Apr 20, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data on its antiepileptic drugs (AED) perampanel (product name: Fycompa) and rufinamide (product name: Inovelon, U.S. product name: BANZEL) will be presented at the 2018 Annual American Academy of Neurology ...
Source: ACN Newswire
Date: April, 20 2018 05:50
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
TOKYO, Apr 19, 2018 - (JCN Newswire) - Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. today announced that the bile acid transporter inhibitor "GOOFICE 5mg Tablet" (nonproprietary name: elobixibat hydrate; development code: AJG533) was...
Source: ACN Newswire
Date: April, 18 2018 23:07
Week In Review: Ping An Good Doctor Plans $1 Billion Hong Kong IPO In Mid-May
Deals and Financings Ping An Insurance (Group) (PIAIF) (PNGAY) plans to carve out its Ping An Healthcare and Technology (also known as Ping An Good Doctor APP) and IPO in Hong Kong for $1 billion at a valuation of $5 billion. The company plans to go public in the middle of May. In May 2016...
Source: SeekingAlpha
Date: April, 15 2018 06:05
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
On the Development of a Potential New Treatment for Tuberculosis TOKYO, Apr 13, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a joint research agreement with the Broad Institute, Mycobacteria Research Laboratories at Colorado State University, and the Unive...
Source: ACN Newswire
Date: April, 13 2018 01:22
Alzheon Proposes Terms For $70 Million IPO
Quick Take Alzheon ( ALZH ) intends to raise $70 million in a U.S. IPO of its common stock, according to an amended S-1/A registration statement . The company is a later stage firm re-developing a potential treatment for Alzheimer’s disease. ALZH is operating in an especially d...
Source: SeekingAlpha
Date: April, 03 2018 14:25
Eisai Submits Supplemental New Drug Application to U.S. FDA
For Fycompa as Treatment for Pediatric Patients with Epilepsy TOKYO, Apr 2, 2018 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Eisai's anti-epileptic drug (AED) Fycompa (per...
Source: ACN Newswire
Date: April, 02 2018 00:44
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
TOKYO, Mar 28, 2018 - (JCN Newswire) - Eisai Co., Ltd. and Nichi-Iko Pharmaceutical announced today that they have entered into a strategic alliance agreement as well as a share transfer agreement for a capital and business alliance, aiming to expand and grow the generic pharmaceutical busines...
Source: ACN Newswire
Date: March, 28 2018 06:33


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ESALF.

About Eisai Co., Ltd. (OTC: ESALF)

Logo for Eisai Co., Ltd. (OTC: ESALF)

Eisai Co. and its subsidiaries are engaged in the manufacture and sale of pharmaceuticals, consumer health care products, diagnostic products, chemicals and food additives, and animal health products. Co. s products include antiallergy agent, osteoporosis treatment, gastritis/gastric ulcer medication, vitamins, food preservative, flavoring agent, and sweetening material. Co. is also engaged in the manufacture and sale of pharmaceutical production system and machines.


Contact Information



Current Management

  • Haruo Naito / President, CEO
  • Hideaki Matsui / CFO

Current Share Structure

  • Market Cap: $15,762,530,735 - 03/09/2018
  • Issue and Outstanding: 296,566,900 - 11/30/2011


Daily Technical Chart for (OTC: ESALF)

Daily Technical Chart for (OTC: ESALF)

Stay tuned for daily updates and more on (OTC: ESALF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ESALF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ESALF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ESALF and does not buy, sell, or trade any shares of ESALF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: